Tema Trading & Prediction Markets ETF (DICE)
| Assets | $1.94M |
| Expense Ratio | 0.75% |
| PE Ratio | n/a |
| Shares Out | 80,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 946 |
| Open | 24.27 |
| Previous Close | n/a |
| Day's Range | 24.27 - 25.42 |
| 52-Week Low | 23.72 |
| 52-Week High | 25.69 |
| Beta | n/a |
| Holdings | n/a |
| Inception Date | Sep 8, 2026 |
About DICE
Fund Home PageThe Tema Trading & Prediction Markets ETF (DICE) is an exchange-traded fund that mostly invests in financials equity. The fund is an actively managed portfolio of domestic and foreign Trading and Prediction Markets companies. The portfolio expects to hold at least 15 to 100 constituents, from micro- to large-cap firms, in seeking long-term growth.
News
Kalshi and Polymarket Aren't Public. You Still Buy Them Through an ETF.
A handful of funds have pre-IPO exposure to Kalshi and Polymarket. Investors need to tread cautiously.
Tema Launches Trading & Prediction Markets ETF (DICE)
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Tema ETFs (“Tema”), a leader in actively managed exchange-traded funds, today announced the launch of the Tema Trading & Prediction Markets ETF (DICE).
Eli Lilly completes acquisition of Dice Therapeutics
Eli Lilly and Company (LLY) announced the successful completion of its acquisition of DICE Therapeutics (DICE). The acquisition expands Lilly’s immunology portfolio to include DICE’s novel oral therap...
Eli Lilly extends expiration of tender offer to acquire Dice Therapeutics
Eli Lilly (LLY) announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of common stock of Dice Therapeutics (DICE), for…
Rapt Therapeutics could be valued at ~$7B, says Capital One
Capital One analyst Zegbeh Jallah maintained an Overweight rating and $48 price target on Rapt Therapeutics (RAPT), noting that Eli Lilly’s (LLY) proposed acquisition of DICE Therapeutics (DICE) for $...
Dice Therapeutics downgraded to Market Perform from Outperform at TD Cowen
TD Cowen analyst Marc Frahm downgraded Dice Therapeutics (DICE) to Market Perform from Outperform after Eli Lilly (LLY) announced plans to acquire Dice for $48 per share in cash. The…
Dice Therapeutics downgraded to Market Perform from Outperform at SVB Securities
SVB Securities analyst Thomas Smith downgraded Dice Therapeutics (DICE) to Market Perform from Outperform with a price target of $48, down from $77, to reflect the recently announced acquisition by…
Dice Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Seamus Fernandez downgraded Dice Therapeutics (DICE) to Neutral from Buy after Eli Lilly (LLY) agreed to buy the company in a deal that is expected to close in…
Dice Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar downgraded Dice Therapeutics (DICE) to Neutral from Buy with a $48 price target after Eli Lilly (LLY) announced that it will acquire all outstanding shares…
Dice Therapeutics downgraded to Hold from Buy at Stifel
Stifel analyst Alex Thompson downgraded Dice Therapeutics (DICE) to Hold from Buy with a price target of $48, down from $54, after Eli Lilly’s (LLY) deal to acquire Dice for…
Dice Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Prakhar Agrawal downgraded Dice Therapeutics (DICE) to Neutral from Overweight with a price target of $48, down from $58, after Eli Lilly (LLY) agreed to acquire the…
Dice Therapeutics downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer downgraded Dice Therapeutics (DICE) to In Line from Outperform after Eli Lilly (LLY) agreed to acquire the company for $48 per share. Published first on…
Dice Therapeutics downgraded to Hold from Buy at Canaccord
Canaccord analyst Edward Nash downgraded Dice Therapeutics (DICE) to Hold from Buy with a price target of $48, down from $71, after Eli Lilly (LLY) agreed to acquire the company…
Dice Therapeutics price target raised to $48 from $38 at Wells Fargo
Wells Fargo analyst Derek Archila raised the firm’s price target on Dice Therapeutics (DICE) to $48 from $38 and keeps an Equal Weight rating on the shares following news that…
Eli Lilly to acquire Dice Therapeutics for $48 per share in cash
Eli Lilly (LLY) and Dice Therapeutics (DICE) announced a definitive agreement for Lilly to acquire Dice. Dice is a biopharmaceutical company that leverages its proprietary Delscape technology platform...
This Major Insider is Loading Up on Dice (NASDAQ:DICE) Stock
One of Dice Therapeutics’ (NASDAQ:DICE) key insiders, Ra Capital Management, Llc, recently bought the company’s shares worth $13.5 million. It is worth mentioning that the hedge fund manager owns more...